Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACACIA: Aficamten in Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
2023-505797-15-00Phase 3Completed
- Sponsor
- Cytokinetics
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial in hypertrophic cardiomyopathy (HCM) comparing Aficamten with Placebo (2 arms). Primary endpoints: Change in KCCQ-CSS from baseline to Week 36 and Change in peak VO2 from baseline to Week 36. Started Mar 2024; status: completed.
02
Drugs
aficamten
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on 2023-505797-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505797-15-00.